Compounding Updates: GLP-1 503B Bulks List & Peptides Evaluation

The regulatory landscape for compounded GLP-1 medications and peptide therapies is continuing to evolve in a way that is reshaping both access and operational models across 503A pharmacies, 503B outsourcing facilities, and med spa programs. Recent FDA proposals and interim bulks list updates signal a clear trend toward tighter control of compounding in these high-demand therapeutic categories.

As of 2026, this shift is no longer speculative but is actively unfolding through proposed exclusions, advisory committee reviews, and reclassification of multiple peptide bulk drug substances. Together, these actions are creating a more defined and restrictive framework for how certain medications can be compounded, sourced, and prescribed. However, the final decisions that will affect compounders are not expected until mid-late 2026. 

Regulatory Update: GLP-1 Compounding (503B Bulks List Proposal)

As of April 30, 2026, the FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. If finalized, this would mean outsourcing facilities could no longer compound these agents from bulk drug substances under the 503B pathway, except in situations where a product is formally listed on the drug shortage list.

This proposal reflects a broader regulatory tightening around high-demand, FDA-approved drug classes and the use of compounding as an alternative supply channel.

What this may mean in practice if the proposal is passed:

  • 503B outsourcing facilities would no longer serve as a scalable source of compounded GLP-1 medications outside of shortage conditions

  • Med spa programs relying on bulk or inventory-based access would need to shift toward patient-specific prescribing models

  • 503A pharmacies would remain part of the care pathway, but with increased emphasis on individualized prescriptions and documentation standards

  • Overall access would become more dependent on traditional prescribing and dispensing workflows rather than distributed compounding supply models

While still in the proposal stage (with public comment open until June 29, 2026), the direction signals a continued narrowing of compounding flexibility in high-demand therapeutic categories.

These shifts further reinforce why due diligence in pharmacy and outsourcing facility partnerships is becoming less about sourcing convenience and more about clinical, regulatory, and operational resilience.

Regulatory Context: Peptides and a Shifting Compounding Landscape

Alongside recent activity around GLP-1 medications, the FDA is also reviewing a broader range of peptide bulk drug substances under both 503A and 503B frameworks. This includes the upcoming Pharmacy Compounding Advisory Committee (PCAC) meeting to evaluate several peptides scheduled for July 23–24, 2026, as well as updates indicating that a number of substances are being removed from current interim bulks lists pending further review.

Importantly, many of these peptides now sit in a regulatory “in-between” state—neither clearly supported for routine compounding nor fully resolved through final rulemaking. This creates a period of uncertainty where enforcement discretion, committee recommendations, and future reclassification decisions will directly shape what can be compounded, and under what conditions.

Updates to the Interim 503A Bulks List: Peptide Reclassification in Motion

The FDA has also republished its interim 503A Bulks List with significant updates affecting multiple peptide bulk drug substances.

Key changes include:

  • GHK-Cu (non-injectable use) is being removed from Category 1

  • GHK-Cu (injectable use) is being removed from Category 2 and will undergo further PCAC review

  • Twelve peptide bulk drug substances are being removed from Category 2 within seven days of the notice due to withdrawal of their nominations

The substances being removed include:

  • BPC-157

  • Cathelicidin LL-37

  • Dihexa Acetate

  • Emideltide (DSIP)

  • Epitalon

  • GHK-Cu (injectable routes of administration)

  • KPV

  • PEGylated Mechano Growth Factor (PEG-MGF)

  • Melanotan II

  • MOTs-C

  • Semax (heptapeptide)

  • Thymosin Beta-4 fragment (TB-500 / LKKTETQ)

Several of these peptides are also scheduled for separate PCAC consultation, with additional review expected through 2026 and into early 2027.

Importantly, removal from Category 2 does not automatically create eligibility for compounding under 503A. Instead, it places these substances into a more uncertain regulatory position, where future compounding permissibility will depend on subsequent FDA determinations, committee recommendations, and potential enforcement discretion.

Key considerations now include:

  • Regulatory posture: How a supplier interprets and responds to FDA bulks list changes and advisory committee outcomes

  • Compounding defensibility: Whether products are clearly grounded in patient-specific prescribing (503A) or compliant bulk frameworks (503B where applicable)

  • Supply chain resilience: Access to pharmaceutical-grade APIs and ability to adapt sourcing as regulatory status evolves

  • Documentation and audit readiness: Strength of records supporting compounding decisions under increased scrutiny

In this context, due diligence is no longer static. It is becoming an ongoing assessment of regulatory alignment and adaptability within an increasingly defined compounding framework.

Implications for Supplier Due Diligence

For pharmacies, outsourcing facilities, and med spa operators, these updates reinforce a shifting regulatory environment where peptide availability is becoming increasingly conditional rather than stable.

This has direct implications for supplier evaluation:

  • 503A pharmacies face increased pressure to ensure strict patient-specific prescribing and avoid protocol-driven or quasi-standardized peptide use models

  • 503B outsourcing facilities may see further constraints on which peptides can be compounded from bulk substances, particularly outside of formal Category 1 designation or shortage scenarios

  • Med spas may experience greater variability in peptide availability, requiring closer scrutiny of pharmacy partners’ regulatory posture, sourcing strategy, and ability to adapt to evolving FDA classifications

Taken together, these developments signal a broader tightening of peptide compounding pathways, where supplier due diligence is increasingly defined by regulatory alignment and adaptability rather than product access alone.

What This Means for Med Spas and Pharmacy Partnerships

Taken together, the FDA’s evolving position on GLP-1 medications (semaglutide, tirzepatide, liraglutide) and the broader reassessment of peptide bulk drug substances signals a clear directional shift: high-demand therapeutic categories that have been widely accessed through compounding channels are now moving into a more narrowly defined regulatory framework.

For med spas—where GLP-1 programs and peptide-based protocols represent a common service offering alongside IV therapies and hormone optimization—this creates a possible structural change in how medications are sourced and delivered.

Rather than a stable “compounding supply layer,” the landscape is increasingly defined by:

  • Reduced scalability of bulk compounding pathways (particularly under 503B)

  • Greater emphasis on true patient-specific prescribing under 503A frameworks

  • Ongoing reclassification of peptides through advisory review and bulks list revisions

  • Higher sensitivity around what constitutes compliant use versus programmatic or protocol-driven distribution models

If you operate a medical spa, our recent Med Spa Compliance article reviews key trends, risks, and provides guidance. 

What to Expect Further into 2026

Looking ahead, the remainder of 2026 is likely to be defined by continued regulatory clarification.

Several key developments are expected to shape the landscape:

  • Finalization of GLP-1 bulks list decisions: The FDA’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list is expected to progress through the public comment and review process. If finalized, this will significantly limit bulk-compounded access outside of documented shortage scenarios.

  • Ongoing PCAC review of peptide substances: Additional Pharmacy Compounding Advisory Committee evaluations scheduled through July 2026 and beyond will likely determine the long-term status of multiple peptides currently in interim or transitional categories.

  • Continued reclassification of interim bulks list entries: As withdrawals, category removals, and reassignments continue, more peptide substances may move into uncertain regulatory status before final determinations are issued.

  • Greater enforcement clarity around compounding pathways: Both 503A and 503B frameworks are expected to see more explicit interpretation regarding what constitutes compliant compounding versus non-defensible supply models, particularly for high-demand therapies.

  • Increased documentation and prescribing scrutiny: Across settings, there will likely be stronger expectations around patient-specific justification, sourcing transparency, and audit-ready documentation to support compounding decisions.

Overall, 2026 is shaping up to be a transition year where compounding access for GLP-1s and peptides becomes less about availability and more about clearly defined regulatory alignment, clinical justification, and operational defensibility.

References

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. (2026). https://www.fda.gov/media/94155/download 

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. (2026). U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list 

July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committ. (2026). U.S. Food and Drug Administration. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 

Disclaimer: This article is intended to provide general information on U.S. compounding. It should not be construed as legal, regulatory, or medical advice. Readers are encouraged to consult an attorney for guidance specific to their circumstances. 

503BAna Aleksic503B